Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04804072 · ClinicalTrials.gov registry record · NA
INTEGRA: A Vanguard Study of Health Service Delivery in a Mobile Health Delivery Unit
A NA study, sponsored by HIV Prevention Trials Network.
- Completed
- Registry status
- NA
- Development phase
- 447
- Enrollment target
NCT04804072: Completed NA study, sponsored by HIV Prevention Trials Network.
NCT04804072 is a NA study that has completed, run by HIV Prevention Trials Network. The registered enrollment target is 447 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (68% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04804072, a NA study, has completed, sponsored by HIV Prevention Trials Network.
- COMPLETED
- Registry status
- NA
- Development phase
- 447 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the efficacy of using a mobile health delivery unit ("mobile unit") to deliver "one stop" integrated health services - particularly medication for opioid use disorder (MOUD) and medication for HIV treatment and prevention - to people who inject drugs (PWID) with opioid use disorder (OUD) to improve uptake and use of MOUD, and uptake and use of antiretroviral therapy (ART) or pre-exposure prophylaxis (PrEP).
Primary Outcome
Documented current use of MOUD. At the Week 26 visit: 1. Alive 2. Retained 3. Biological evidence of MOUD (any detectable Methadone or Buprenorphine) 4. A MOUD prescription current at the week 26 visit or proof of current receipt of MOUD from a clinic that does not provide individual MOUD prescriptions (e.g., methadone clinics)
Interventions
- DRUG Medication for opioid-use disorder (MOUD) for opioid-use disorder (OUD)
- DIAGNOSTIC_TEST HIV testing
- DRUG HIV treatment for participants living with HIV not already in care
- DRUG PrEP for participants without HIV
- DIAGNOSTIC_TEST Testing and referral for vaccination or treatment for hepatitis A virus (HAV) and hepatitis B virus (HBV)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 447 participants |
| Start Date | 2021-06-02 |
| Est. Completion | 2024-12-17 |
| Phase | NA |
What the finished NCT04804072 record still lists
NCT04804072 is an interventional study that assigns participants to a tested intervention. The registered 447 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (68% lower).
The record links to 0 conditions, and to 5 interventions - of which Medication for opioid-use disorder (MOUD) for opioid-use disorder (OUD) is the first listed.
NCT04804072 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04804072 about?
NCT04804072 is a clinical study titled "INTEGRA: A Vanguard Study of Health Service Delivery in a Mobile Health Delivery Unit". The purpose of this study is to determine the efficacy of using a mobile health delivery unit ("mobile unit") to deliver "one stop" integrated health services - particularly medication for opioid use disorder (MOUD) and medication for HIV treatment and prevention - to people who inject drugs (PWID) ...
What is the current status of trial NCT04804072?
This trial is currently completed. It is a NA study. The enrollment target is 447 participants. The study started on 2021-06-02. Estimated completion is 2024-12-17.
What interventions are being tested in trial NCT04804072?
The interventions under investigation include: Medication for opioid-use disorder (MOUD) for opioid-use disorder (OUD) (DRUG), HIV testing (DIAGNOSTIC_TEST), HIV treatment for participants living with HIV not already in care (DRUG), PrEP for participants without HIV (DRUG), Testing and referral for vaccination or treatment for hepatitis A virus (HAV) and hepatitis B virus (HBV) (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04804072?
This trial is sponsored by HIV Prevention Trials Network, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04804072's enrollment target sits among peer trials
447 233rd of 2000 higher than 1,768 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04065399 · 447 participants · Phase 1
A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
- NCT06702449 · 448 participants · Phase 1
A Study on the Safety and Immune Response of a Urinary Tract Infection (UTI) Vaccine in Adults 18-64 Years of Age and Clinical Efficacy in Females 18-64 Years of Age
- NCT07125053 · 448 participants · NA
COPD Resources, Education, and Activity Designed for You Study
- NCT01280994 · 445 participants · Phase 2
Hyperpolarized 129Xe MRI for Imaging Pulmonary Function
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI